ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Friday, November 6, 2020

3:00PM-3:50PM: Abstract Number: 0508

Maintenance or Achievement of Minimal Disease Activity Following Therapy Optimization with Adalimumab or Methotrexate in Patients with Psoriatic Arthritis: Results from Part 2 of a Randomized, Open-Label Phase 4 Study

Spondyloarthritis Including Psoriatic Arthritis – Treatment I: Psoriatic Arthritis (0504–0508)

3:00PM-3:50PM: Abstract Number: 0513

Mass Spectrometry Identifies Novel Biomarkers in Giant Cell Arteritis, Useful in Patients on Interleukin-6 Receptor Blockade

Vasculitis – Non-ANCA-Associated & Related Disorders I: GCA, Behçet’s, & Relapsing Polychondritis (0509–0513)

3:00PM-3:50PM: Abstract Number: 0453

Monitoring of BK Reactivation and Long-term Safety on JAK1/2 Inhibition with Baricitinib

Immunological Complications of Therapy (0449–0453)

3:00PM-3:50PM: Abstract Number: 0451

Prevalence, Therapy and Tumor Response in Patients with Rheumatic Immune-related Adverse Events Following Immune Checkpoint Inhibitor Therapy: A Single-Centre Analysis

Immunological Complications of Therapy (0449–0453)

3:00PM-3:50PM: Abstract Number: 0452

Recombinant Zoster Vaccine in Patients with Rheumatic Diseases: A Retrospective Study of 622 Patients

Immunological Complications of Therapy (0449–0453)

3:00PM-3:50PM: Abstract Number: 0505

Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial

Spondyloarthritis Including Psoriatic Arthritis – Treatment I: Psoriatic Arthritis (0504–0508)

3:00PM-3:50PM: Abstract Number: 0481

Subclinical Synovitis in Arthralgia: How Often Does It Result in Clinical Arthritis? A Longitudinal Study to Reflect on Starting Points for DMARD Treatment

RA – Diagnosis, Manifestations, & Outcomes I: Pre-Onset & Early RA (0479–0483)

4:00PM-4:50PM: Abstract Number: 0515

A Proof of Concept Study to Assess the Efficacy of Tocilizumab in Combination with Ultra-Short Glucocorticoid Administration to Treat Newly Diagnosed Giant Cell Arteritis – a 24 Week Analysis

Vasculitis – Non-ANCA-Associated & Related Disorders II: GCA Clinical & Epidemiology (0514–0518)

4:00PM-4:50PM: Abstract Number: 0487

Association Between an Extended Lifestyle Score and Adverse Health-related Outcomes in People with Rheumatoid Arthritis: A Study of 5295 UK Biobank Participants

RA – Diagnosis, Manifestations, & Outcomes II: The Heart of the Matter (0484–0488)

4:00PM-4:50PM: Abstract Number: 0434

Changes in Mental Health During the COVID-19 Pandemic Among Individuals with Rheumatic Disease

Clinical Practice I (0434–0438)

4:00PM-4:50PM: Abstract Number: 0516

Characteristics of Giant Cell Arteritis Flares After Successful Treatment with Tocilizumab: Results from the Long-Term Extension of a Randomized Controlled Phase 3 Trial

Vasculitis – Non-ANCA-Associated & Related Disorders II: GCA Clinical & Epidemiology (0514–0518)

4:00PM-4:50PM: Abstract Number: 0486

Differences in Low-density Lipoprotein (LDL) Particle Composition and Oxidation May Underlie the Paradoxical Association of Low LDL with Higher Coronary Atherosclerosis Burden in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes II: The Heart of the Matter (0484–0488)

4:00PM-4:50PM: Abstract Number: 0442

Disparities in CoronaViridae Infection Are Readily Apparent in Rheumatology Patients Despite Use of Hydroxychloquine And/or Methotrexate

Healthcare Disparities in Rheumatology (0439–0443)

4:00PM-4:50PM: Abstract Number: 0514

Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor the Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Observational Cohort Study

Vasculitis – Non-ANCA-Associated & Related Disorders II: GCA Clinical & Epidemiology (0514–0518)

4:00PM-4:50PM: Abstract Number: 0439

Hurried Communication and Low Patient Self-Efficacy Are Associated with Persistent Non-Adherence to SLE Medications

Healthcare Disparities in Rheumatology (0439–0443)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].